Published in final edited form as:

J Nat Prod. 2010 March 26; 73(3): 428–434. doi:10.1021/np900638e.

Synthesis of 7-¹⁵N-Oroidin and Evaluation of Utility for Biosynthetic Studies of Pyrrole-Imidazole Alkaloids by Microscale ¹H-¹⁵N HSQC and FTMS†

Yong-Gang Wang[‡], Brandon I. Morinaka[§], Jeremy Chris P. Reyes[‡], Jeremy H. Wolff[⊥], Daniel Romo^{*,‡}, and Tadeusz F. Molinski^{*,§,||}

Department of Chemistry, Texas A&M University, P.O. Box 30012, College Station, Texas 77842-3012, Bruker Daltonics, 40 Manning Rd, Billerica, Massachusetts, 01821, and Department of Chemistry and Biochemistry, and Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, 9500 Gilman Drive, La Jolla, California, 92093-0358, USA.

Abstract

Numerous marine-derived pyrrole-imidazole alkaloids (PIAs), ostensibly derived from the simple precursor oroidin, **1a**, have been reported and have garnered intense synthetic interest due to their complex structures and in some cases biological activity; however very little is known regarding their biosynthesis. We describe a concise synthesis of 7-¹⁵N-oroidin (**1d**) from urocanic acid and a direct method for measurement of ¹⁵N incorporation by pulse labeling and analysis by 1D ¹H-¹⁵N HSQC NMR and FTMS. Using a mock pulse labeling experiment, we estimate the limit of detection (LOD) for incorporation of newly biosynthesized PIA by 1D ¹H-¹⁵N HSQC to be 0.96 μg equivalent of ¹⁵N oroidin (2.4 nmole) in a background of 1500 μg unlabeled oroidin (about 1 part per 1600). 7-¹⁵N-Oroidin will find utility in biosynthetic feeding experiments with live sponges to provide direct information to clarify the pathways leading to more complex pyrrole-imidazole alkaloids.

The polycyclic pyrrole-imidazole alkaloid (PIA) family has received much attention recently from the synthetic organic communityⁱ because of their challenging molecular structure, dense functionality and potential biological activity. All are believed to derive from a simple common sponge metabolite; most likely oroidin (**1a**) or its analogs hymenidin (**1b**) and clathrodin (**1c**), the structures of which differ only in bromine content.ⁱⁱ Representative of the members of this family are the dimeric PIAs scepterin (**2**),ⁱⁱⁱ ageliferin (**3**),^{iv} massadine (**4**),^v palau'amine (**5**)^{vi} and axinellamines A and B (**6a-b**),^{vii} and higher-order tetrameric PIAs.^{viii} In addition, compact monomeric polycyclic PIAs, such as agelastatins A,^{ix} B,^x C and Dxi (**7a-d**) and dibromophakellin^{xii} appear to be derived from oxidative intramolecular cyclizations of oroidin (**1a**) or hymenidin (**1b**). PIAs are of contemporary interest due to their potent biological activity and intriguing biosyntheses. For example, (–)-agelastatin A

[†]Dedicated to the late Dr. John W. Daly of NIDDK, NIH, Bethesda, Maryland and to the late Dr. Richard E. Moore of the University of Hawaii at Manoa for their pioneering work on bioactive natural products

^{*}To whom correspondence should be addressed: Tel: +1 (858) 534-7115. Fax: +1 (858) 822-0386. tmolinski@ucsd.edu. Tel: +1 (979) 845-9571. Fax: +1 (979) 862-4880. romo@tamu.edu..

[‡]Texas A&M University, Department of Chemistry

[§]UC San Diego, Department of Chemistry and Biochemistry

[⊥]Bruker Daltonics

^{||}UC San Diego, Skaggs School of Pharmacy and Pharmaceutical Sciences

Supporting Information Available.

Synthetic procedures and ¹H and ¹³C NMR spectra for **1d**, **9-16**, other intermediates and calculation of LOD for ¹H-¹⁵N HSQC experiments. This material is available free of charge via the Internet at <http://pubs.acs.org>.

(**7a**), an antitumor PIAx is 1.5-16 times more active than cisplatin against a range of tumor cell lines, and potently inhibits osteopontin, an adhesion glycoprotein transcriptionally regulated by the Wnt β -catenin pathway and implicated in tumor progression, dissemination, and metastases.xiii

The widely accepted hypothesis for biosynthesis of dimeric and tetrameric PIAs, involves dimerization of oroidin (**1a**) followed by consecutive oxidative transformations leading to more densely functionalized, polycyclic alkaloids.viii In 1982, Büchi reported a 'biomimetic' synthesis of the simple PIA, racemic dibromophakellin, by oxidative cyclization of 9,10-dihydrooroidin.xiv The structure of sceptrin (**2**) is highly suggestive of a formal [2+2] cycloaddition of two molecules of hymenidin (**1b**) to **2**; however, despite many attempts, Faulkner, Clardy and co-workers were unable to achieve photodimerization of **1b** to **2**,iii suggesting that an alternative non-concerted mechanism may be responsible for the biosynthesis. Recent speculation on the order of biosynthesis of **2** and **3** revolves around ionic mechanisms of ring-expansion, supported by the demonstrated conversion of **2** to **3** under thermal conditions, if,xv,xvi or a ring-contraction pathway from an ageliferin-type dimer generated by a Diels Alder type cycloaddition of two molecules of hymenidin (**1b**).ii For example, one speculative hypothesis invokes a cycloaddition in the biosynthesis of palau'aminevib and axinellamine, followed by a stepwise electrophilic chlorination and ring contraction. Remarkably, none of the above hypotheses have been tested experimentally in live sponges.

We describe here a synthesis of ^{15}N -labeled oroidin (**1d**) and optimization of conditions for detection of ^{15}N -incorporation by microscale FTMS and ^1H - ^{15}N HSQC using a 'mock' pulse-labeling experiment with **1d** and natural oroidin (**1a**). We estimate the limits of detection of these methods and determine their suitability for use in field incorporation for biosynthetic studies of complex PIAs with living sponges. This information can be used to answer biosynthetic questions of the biosynthesis of PIAs by sponges in the genera *Agelas*, *Stylissa* and *Ptilocaulis*.

Results and Discussion

Several syntheses of oroidin have been described in the literature and the synthetic approaches utilized can be classified into two categories.xvii The first involves synthesis of the required 2-aminoimidazole ring by condensation of a guanidine derivativexviii or cyanamidexix with an α -haloketone. An alternative strategy involves amination of an imidazole ring via azido or diazonium transfer reagents.xx We elected the latter strategy for brevity and the utility of the commercially available, starting material urocanic acid, as demonstrated by Lovely.io,xxi This strategy enabled a late-stage introduction of the ^{15}N -label which is ideal for cost considerations (Scheme 1). Disconnection of the amide bond leads to the known 4,5-dibromo-2-trichloroacetylpyrrole **8**,xxib,c readily synthesized from commercially available 2-trichloroacetylpyrrole, and the ^{15}N -labeled allylic amine **9** which could be obtained by a lithiation/azidation sequence at the 2-position of the *N*-protected urocanic acid ester **10**. The ^{15}N label would be introduced towards the end of the overall sequence by Gabriel synthesis employing the potassium salt of commercially available ^{15}N -phthalimide and an activated derivative of the alcohol, that in turn, could be obtained by reduction of the carbomethoxy group of ester **10**.

Fisher esterification of urocanic acid with methanol (Scheme 2) and subsequent protection gave the known *N*-trityl imidazole derivative **10**. xxii Reduction of ester **10** (DIBAL-H) afforded the corresponding alcohol **11** in excellent yield. Initial attempts to execute a direct azidation of alcohol **11** at the 2-imidazole position with the unprotected alcohol using known procedures (*n*-BuLi/ TsN_3),xxc-e gave none of the desired azido product. Instead, the

product obtained was tentatively assigned the structure of a triazene-imidazole derivative based on ^1H NMR and mass spectrometric analysis.^{xxiii} When the TBS protected imidazole **12** was subjected to the previously employed conditions for azido-transfer, azide **13** was obtained in excellent yield. Deprotection of silyl ether **13** with TBAF afforded alcohol **14**, which was then subjected to mesylation (MsCl , Et_3N). Without purification, the mesylate was treated with the potassium salt of ^{15}N -phthalimide (>98% atom ^{15}N) to provide the ^{15}N -labeled phthalimide **15**. Cleavage of phthalimide **15** with NH_2NH_2 furnished the ^{15}N -allylic amine **9** which was acylated with 4,5-dibromo-2-trichloroacetylpyrrole (**8**) to provide ^{15}N -pyrrolocarboxamide **16** in good overall yield. Removal of the trityl group from **16** with anhydrous methanolic HCl , generated in situ from acetyl chloride and MeOH , afforded the corresponding 2-azido imidazole^{xxc} that was hydrogenated in the presence of Lindlar's catalyst to provide 7- ^{15}N -oroidin (**1d**, >98% atom ^{15}N).

The ^1H , ^{13}C and ^{15}N NMR spectra and mass spectra were fully consistent with the structure and location of the ^{15}N label as depicted. The FTMS of natural oroidin (**1a**, Figure 2) shows the expected 1:2:1 pattern for the pseudomolecular ion $[\text{M}+\text{H}]^+$ associated with the ^{79}Br and ^{81}Br isotopomers (m/z 387.93990, $\Delta\text{mmu} = -0.41$ mmu). The FTMS spectrum of 7- ^{15}N -oroidin (**1d**) (Figure 2b) shows the same ion pattern, only the distribution is increased by 1 amu (m/z 388.93719, $\Delta\text{mmu} = -0.16$). Less than 2% of the ^{14}N isotopomer was detected which is consistent with the reported purity of the ^{15}N -phthalimide (>98% atom ^{15}N) employed in the synthesis.

Two general methods are available for measuring incorporation of the stable isotope ^{15}N into natural products by pulse labeling – mass spectrometry and NMR. In both techniques, the level of isotopic enrichment from *de novo* biosynthesis of derived PIAs must exceed the background ^{15}N present of extant PIAs within the sponge *and*, for MS in particular, ^{15}N background contributions from other nitrogen atoms in the molecule. As a stable isotope label, ^{15}N is preferable to ^{13}C because the natural abundance of the heavier to lighter isotope for N (~0.3%) is only about 1/4 of C (~1.1%). ^{15}N incorporation will, therefore, be easier to detect. Ideally for ^{15}N incorporation experiments, mass spectrometry should differentiate the contributions to the $\text{M}+1$ peak from ^{15}N and ^{13}C ,^{xxiv} a task best-suited to Fourier transform MS (FTMS) with exceptionally high resolution (7T field, $R = 240,000$) that should be capable of resolving the nominal $\text{M}+1$ peak of the pseudomolecular ion into individual isotopomer contributions from species containing one ^{13}C or one ^{15}N . Baseline separation of the isotopomers was readily achieved by MALDI FTMS (Figure 3), allowing quantitation of the ^{15}N isotopomer peak. For oroidin (**1a**), the critical *difference* in the mass of ^{12}C - ^{15}N containing ions versus the heavier ^{13}C - ^{14}N isotopomer amounts to only 0.00632 amu, a baseline separation not readily achievable by high-resolution mass spectrometers with conventional analyzers (e.g. double sector, TOF).

Quantitation of the ^{15}N isotopomer can be made from integration of ion current intensities of the $[\text{M}+1]$ components, ^{15}N - ^{12}C and ^{14}N - ^{13}C (Figure 3). Assuming the ^{13}C abundance in *natural* and *synthetic* ^{15}N -labeled oroidin are identical, the ^{13}C peak intensity may be used as the denominator in the ratio h (Equation 1), where h_{N} and h_{C} are the respective measured peak heights of the ^{15}N - ^{12}C and ^{14}N - ^{13}C component ions.

$$h = h_{\text{N}} / h_{\text{C}} \quad (\text{Eqn 1})$$

Consequently, h can be used to reflect small changes in the ^{15}N content.^{xxv} From the ion current peak heights measured in the FTMS spectrum of natural oroidin (**1a**), h was found to be 0.1487 ± 0.0175 . A prepared 'mock' labeled sample ('Mix1'), consisting of a 1:0.005 mixture of oroidin (**1a**): 7- ^{15}N -oroidin (**1d**), showed an enhanced h of 0.1881 ± 0.0135 corresponding to a ~4% ^{15}N enrichment. A second sample ('Mix2', 1:0.100, **1a**:**1d**) gave h

= 1.024 ± 0.0369 , corresponding to ~88% ^{15}N enrichment. We estimate that the limit of detection (LOD, $\pm 3 \sigma$) for ^{15}N incorporation corresponds to an increase in intensity, Δh ~5.2%. Given that natural abundance of ^{15}N is approximately 0.3% atom, this would amount to observation of as little as 10.4 parts per thousand of ^{15}N incorporation per N atom of oroidin (**1a**) by *de novo* synthesis. Detection of this small amount will, of course, be made more difficult by the presence of unlabeled oroidin (**1a**) within the sponge.

The disadvantage of analysis of ^{15}N -content in oroidin and other PIAs by MS is the presence of at least five N atoms, each contributing to the intensity of ^{15}N - ^{12}C component of the M+1 peak. Consequently, it may be expected the actual LOD by FTMS will be higher.

Direct detection of ^{15}N incorporation by ^{15}N NMR spectroscopy is impractical due to low natural abundance and severely compromised sensitivity of this $I = \frac{1}{2}$ nucleus which possesses a low-magnitude, negative magnetogyric ratio ($\gamma = -4.31726570 \text{ MHz T}^{-1}$).xxvi Conveniently, ^1H - ^{15}N HSQC circumvents most of these problems by indirect detection of bonded ^1H - ^{15}N couplets through magnetization transfer from ^{15}N and observation of the more sensitive ^1H nucleus. Because four of the five N atoms in oroidin (**1a**) are bonded to H, 2D ^1H - ^{15}N HSQC can provide bond-specific information about fractional enrichment at an individual N atom in oroidin and, by extension, more complex PIAs by measurement of the ^1H - ^{15}N couplet intensity. The intensity of cross peaks in the 2D ^1H - ^{15}N HSQC spectrum of oroidin will vary for each N-H couplet depending on efficiency of magnetization transfer that largely depends upon the magnitude of the $^1J_{\text{NH}}$ scalar coupling constant. Nevertheless, the intensity of each crosspeak will scale linearly as a function of ^{15}N abundance.

When put to practice, it is easier and more meaningful to measure ^{15}N enrichment from the volume integration of cross peaks of 2D HSQC spectra or – best of all – from the 1D version of the HSQC experiment where evolution of the F1 dimension (^{15}N chemical shift) is eliminated and acquisition time is devoted to improving S/N in the detected dimension F2 (^1H chemical shift). We define here ΔI as the *difference* of cross peak intensity, I , of the ^{15}N -labeled N-H couplet of interest (in this case, the NH(C=O) signal of **1d**) in a sample of oroidin (**1a**), spiked with a known amount of 7- ^{15}N -oroidin (**1d**), compared to the intensity, I_0 , of oroidin recorded under the same conditions (Equation 2). The values of I are normalized to the intensity of the pyrrole N-H couplet of oroidin, I_{py} , in each experiment.

$$\Delta I = (I - I_0) / I_0 \quad (\text{Eqn. 2})$$

We elected to use the pyrrole N-H couplet of oroidin (**1a**) ($\delta_{\text{H}} = 13.14$, s; $\delta_{\text{N}} 169.1$) as the control because of its ready assignment from ^1H - ^{15}N HMBC, lack of tautomerism, and likely origination in a different biosynthetic pathway unaffected by biosynthetic incorporation of ^{15}N into the amino-imidazole fragment (see Discussion).

The exquisite mass-sensitivity of the triple-tuned $\{^{13}\text{C}, ^{15}\text{N}\}^1\text{H}$ 1.7 mm 600 MHz microcryoprobe was used to full advantage in this work for characterization of the ^{15}N content of oroidin samples. This low-volume, high-mass sensitivity cryoprobe allowed measurements of samples of only ~1.5 mg in 30 μL (acquisition times, ~4 h). Figure 4 shows the 2D ^1H - ^{15}N HSQC experiment for oroidin (**1a**) with respective N assignments (also, see the Experimental for accurate δ 's). A single dominant cross peak was observed in the 2D ^1H - ^{15}N HSQC of 7- ^{15}N -oroidin (**1d**) (not shown), confirming the location of the ^{15}N label at the amide group N-H ($\delta_{\text{H}} = 8.75$, t, $^3J_{\text{HH}} = 6.0 \text{ Hz}$, H7; $\delta_{\text{N}} = 107.8$, N7), as expected.

Figure 5a-c shows 1D ^1H - ^{15}N HSQC experiments of oroidin (**1a**) spiked with different amounts of 7- ^{15}N -oroidin (**1d**) and the integrals of each N-H couplet, normalized to the N1-

pyrrole couplet are reported in Table 1 (note that the integrals are not exactly proportional to the stoichiometric ratios of attached H's). As predicted, the value of ΔI increases linearly with the amount of added 7- ^{15}N -oroidin (**1d**) and the slope of this 'standards addition' linear regression (Figure 6) gives the proportionality constant $c = 0.34$ for ΔI per μg of added **1d**. It should be noted that this value will be highly dependent upon the pulse sequence parameters and conditions used for NMR acquisition.

Constant c will be useful for estimation of absolute %N incorporations in PIAs labeled during in-field incorporation experiments of secondary metabolism within living sponges. Although it is advisable to measure the relative HSQC intensities of pyrrole N-H couplet and NH(C=O) couplets of the specific PIA in question, it may be reasonably expected that the magnetic properties of these couplets in more complex PIAs are comparable to those of oroidin (**1a**). We estimate the limit of detection (LOD) for ^{15}N enrichment by HSQC in **1a** to be approximately 1.5 parts per thousand (based on ± 3 SD). This is *more sensitive* than the LOD of ^{15}N -enrichment by FTMS, the reason being HSQC detection of couplet ^{15}N - ^1H at each N atom and eliminates background 'dilution' by other ^{15}N 's, however the precision is inferior to FTMS replicate measurements.

Biosynthetic Considerations

Two phases of PIA biosynthesis can be considered: the assembly of oroidin (**1a**), and downstream conversion of the latter to more complex PIAs. Despite much speculation, on the biosynthesis of PIAs, only one experimental study in living marine sponges has appeared to date. The precursor for the imidazole side chain is probably an amino acid and both histidine and ornithine have been proposed.^{xxvii} Kerr and co-workers found that cultured cells of *Teichaxinella morchella* (*Styllisa caribicaxxviii*) produced ^{14}C -labeled stevensine (**17**),^{xxix} the simplest monomeric PIA related to oroidin (**1a**), upon exposure to U- ^{14}C -labeled histidine or C5- ^{14}C -ornithine, but not U- ^{14}C -arginine (Figure 7).^{xxvii} Paradoxically, U- ^{14}C -histidine was incorporated into **17**, but this would require an additional C_1 unit from an unidentified source to complete the imidazole ring and a non-intuitive substitution of NH_2 at C-2 of the imidazole ring. No simple mechanism for this scenario presents itself. Alternatively, citrulline from the *N*-carbamoylation of ornithine, may be the precursor to the side chain of oroidin; however ornithine is also a precursor for the biosynthesis of the pyrrole group; this hypothesis would not be resolved by labeled ornithine incorporation experiments. Ornithine, if it is the precursor to oroidin (**1a**), must undergo decarboxylation, amide coupling with a suitable pyrrole carboxylate group, *N*-carbamoylation to citrulline, oxidative *N*-insertion into the side chain and aromatization of the heterocyclic product to give the nascent 2-aminoimidazole ring (Figure 7).

These uncertainties in the origin of oroidin (**1a**) are, in theory, addressable by suitable ^{15}N -labeled amino acid incorporation experiments. Unfortunately, low levels of radioactivity and specific incorporation levels were observed with amino acids in the Kerr experiment ([U- ^{14}C]-His, 1460 dpm (0.026%) and [U- ^{14}C]-ornithine, 1300 dpm (0.024 %), respectively^{xxvii}), presumably, a consequence of the low numbers of cultured cells used (5×10^7) and higher metabolic mobilization and dilution of ^{14}C -labeled amino acids into other committed pathways of primary metabolism. Consequently, detection of ^{15}N incorporation into PIAs using ^{15}N -labeled amino acids may be precluded by the limits of detection. For the above reasons, late-stage precursors (*e.g.* 7- ^{15}N -oroidin (**1d**), sceptrin (**2**) and ageliferin (**3**)) are attractive for mapping the origin of downstream polycyclic PIAs since these molecules should be committed intermediates. Measurement of their rates of incorporation into PIAs in living sponges of the genera *Agelas*, *Styllisa* and *Ptilocaulis* may also provide critical data on the rates of marine alkaloid secondary metabolism for which there is no current information.

The use of precursors labeled with the spin $I=1/2$ stable isotope ^{15}N is particularly attractive as it provides bond-specific information regarding the flow of intermediates in biosynthesis of complex PIAs. Judicious design and placement of the label in ^{15}N -labeled oroidin is important. Because the primary NH_2 group of the aminoimidazole group is potentially metabolically labile through deamination reactions, we chose to label the amide bond in ^{15}N -oroidin. Quantitation of ^{15}N incorporation into proteins has been made from integration of cross peak volumes of 2D HSQC experiments;xxx however, in the present work with natural products we show that it is far simpler to integrate the corresponding 1D HSQC spectra.

Finally, although the ratio of scep trin to ageliferin found in one sample of *Agelas conifera* is ~10:1,xxx the ratios of mono-brominated and dibrominated analogs of scep trin and ageliferin vary slightly from approximately 1:1 ~ 3:4; however, these data do not clearly indicate an ordering for a bromination-dimerization sequence in the biosynthesis of dimeric PIAs. Propagation of 7- ^{15}N -oroidin (**1d**) along the biosynthetic pathway to complex PIAs will carry the ^{15}N label through symmetrical and non-symmetrical intermediates and detection of residual ^{15}N in strategically chosen N-H bonds in the molecule should reveal timing, ordering and molecularity of the C-C bond-forming events and the extent of coupling of *de novo* enzymatic reactions. HPLC analysis of PIA-containing extracts from *A. conifera* (Agelasidae), collected in the Florida Keys by Köck and coworkers,xxx show the presence of scep trin (**2**) and ageliferin (**3**), however, some specimens of *Agelas scep trum* collected by us contained scep trin (**2**) but were devoid of the expected precursors **1a-c**. If **1a-c** are precursors to other PIAs, as is highly probable, this implies that the *rates* of conversion of **1a-c** to higher-order PIAs are highly dependent upon the sponge species, their biosynthetic capacities, and possibly the habitats they occupy. 7- ^{15}N - Oroidin (**1d**) should find great value in systematic studies of the time-dependent biosynthesis of PIA natural products by pulse labeling in live sponges to answer some of these questions.

Conclusion

A concise, gram-scale synthesis of ^{15}N -labeled oroidin from commercially available and inexpensive urocanic acid has been achieved. ^{15}N -Oroidin, or its debromoanalogs, may be utilized in biosynthetic feeding experiments to elucidate likely intermediates in the biosynthesis of complex members of the pyrrole-imidazole marine alkaloid family, including palau'amine and axinellamine. FTMS detection of ^{15}N offers unparalleled sensitivity (picomole) and ^1H - ^{15}N HSQC provides bond-specific information. The utility of ^1H - ^{15}N HSQC experiments for detection of site-specific ^{15}N incorporation in a mock pulse-labeling experiment has been demonstrated. Several advantages of ^{15}N pulse labeling of biosynthetic pathways are apparent, especially for in-field experiments carried out with living marine invertebrates. The ^{15}N NMR chemical shift was exploited through indirect ^1H - ^{15}N HSQC to afford enhancement of otherwise weak ^{15}N signals by polarization transfer through N-H couplets. ^{15}N incorporation was further amplified by the enhanced mass-sensitivity of the triple-tuned $^1\text{H}\{^{13}\text{C},^{15}\text{N}\}$ -600 MHz 1.7 mm microcryoprobe. Biosynthetic studies with alkaloids bearing N-H groups that are not complicated by exchange or tautomerism afford the best cases for application of the technique. In principle, even alkaloids lacking N-H couplets (tertiary N compounds) are amenable to study by detection of long-range ^1H - ^{15}N couplets from HMBC experiments. The use of ^{15}N stable isotope avoids more complex logistics associated with radioactive tracers (e.g. ^{14}C , ^3H) that often preclude laboratory operations aboard seagoing research vessels. The results of field incorporation experiments with 7- ^{15}N -oroidin (**1d**) will be reported in due course.

Experimental Section

General Experimental Procedures

IR spectra were recorded on thin films using a Jasco 4100 FTIR by attenuated total reflectance (ATR) on samples mounted on a 3 mm ZnSe plate. ^1H and ^{13}C NMR spectra were recorded on a Bruker DRX 600 MHz equipped with 1.7-mm $\{^{13}\text{C}, ^{15}\text{N}\}$ ^1H 600 MHz CPTCI microcryoprobe, JEOL 500 MHz spectrometer equipped a 5 mm $\{^{13}\text{C}\}$ ^1H probe or Varian 400 and 500 MHz spectrometers equipped with 5 mm $\{^{13}\text{C}\}$ ^1H room temperature probe and 5 mm $\{^1\text{H}\}$ ^{13}C cryoprobe, respectively. NMR spectra are referenced to residual solvent signals (CHCl_3 , ^1H , δ 7.26 ppm; CDCl_3 , ^{13}C , δ 77.16 ppm) or the internal offset for ^{15}N assigned by the instrument manufacturer (Bruker). HRMS measurements of synthetic compounds were made at the Laboratory for Biological Mass Spectrometry (Texas A&M University), Scripps Research Institute (TOF-MS) or University of California, San Diego (EI-MS) mass spectrometry facilities. MALDI FTMS were recorded on a 7T Bruker Apex QFTMS. LCMS was carried out on a ThermoFisher Accela UHPLC coupled to an MSQ single quadrupole mass spectrometer operating in positive ion mode, unless otherwise stated. Semi-preparative HPLC was carried out on a Varian SD200 system equipped with a dual-pump and UV-1 UV detector under specified conditions. All solvents for purification were of HPLC grade. See Supporting Information for other procedures.

Synthesis of 7- ^{15}N -Oroidin (1d)—To a solution of amide **16** (380 mg, 0.58 mmol) in 20 mL of EtOAc was added MeOH (1.17 mL, 28.9 mmol) followed by dropwise addition of AcCl (2.06 mL, 28.9 mmol) (to generate HCl) at 0 °C. The solution was stirred for 1.5 h at 25 °C and during that time a precipitate formed. The reaction mixture was filtered to separate the solid product of azidoimidazole hydrochloride salt (240 mg, 99%), which was of sufficient purity for the next reaction: IR (thin film) 3115, 233, 2150, 1611, 1555, 1439 cm^{-1} ; ^1H NMR (500 MHz, CD_3OD) δ 4.11 (d, J = 5 Hz, 2H), 6.35 (dt, J = 16, 3.5 Hz, 1H), 6.43 (d, J = 16 Hz, 1H), 6.89 (d, J = 2 Hz, 1H), 7.31 (s, 1H); ^{13}C NMR (125 MHz, CD_3OD) δ 42.3 (d, $J_{\text{C-N}}$ = 114 Hz), 100.8, 107.3, 115.2, 116.3, 117.5 (d, $J_{\text{C-N}}$ = 22.5 Hz), 129.4 (d, $J_{\text{C-N}}$ = 106 Hz), 131.8, 132.3, 142.6, 162.4 (d, $J_{\text{C-N}}$ = 174 Hz); HRESIMS m/z 416.9171 [$\text{M} + \text{H}$] $^+$ (calcd for $\text{C}_{11}\text{H}_{12}\text{Br}_2\text{N}^{15}_6\text{NO}$, 416.9163).

To a solution of the azidoimidazole hydrochloride salt (210 mg, 0.50 mmol) in 30 mL of MeOH/EtOAc (1 : 1) was added Lindlar's catalyst (100 mg, 5% Pd on CaCO_3 , poisoned with Pb). The resulting mixture was stirred under atmospheric hydrogen at 25 °C for 6 h then filtered with MeOH through a pad of Celite. The filtrate was concentrated under reduced pressure to leave a residue, which was purified by flash column chromatography on silica gel (gradient elution: 10:1:0 $\rightarrow$ 1:1:0.01 $\text{CH}_2\text{Cl}_2/\text{MeOH}/\text{NH}_4\text{OH}$) to furnish 7- ^{15}N -oroidin (**1d**) (165 mg, 84%): IR (thin film): 3304, 2363, 2339, 1620, 1507, 1415 cm^{-1} ; ^1H NMR (500 MHz, CD_3OD) δ 4.00 (d, J = 6 Hz, 2H), 5.87 (dt, $^3J_{\text{NH}}$ = 16 Hz, $^3J_{\text{HH}}$ = 6 Hz, 1H), 6.30 (d, J = 16 Hz, 1H), 6.47 (s, 1H), 6.83 (d, J = 1 Hz, 1H); ^{13}C NMR (125 MHz, CD_3OD) δ 43.1 (d, $^1J_{\text{C-N}}$ = 106 Hz), 100.7, 107.0, 115.1, 118.5, 122.2, 123.6 (d, $^2J_{\text{C-N}}$ = 15 Hz), 129.7 (d, $^1J_{\text{C-N}}$ = 99 Hz), 132.2, 152.8, 162.4 (d, $^1J_{\text{C-N}}$ = 175 Hz); HRESIMS m/z 390.9289 [$\text{M} + \text{H}$] $^+$ (calcd for $\text{C}_{11}\text{H}_{12}\text{Br}_2\text{N}_4^{15}\text{NO}$, 390.9258).

See Supporting Information for additional procedures.

Isolation of Natural Oroidin (1a) from *Stylissa caribica*

A sample of *Stylissa caribica* (wet wt. 24.5 g) was collected in the Bahamas (June 2008) and extracted with 1:1 $\text{CH}_2\text{Cl}_2/\text{MeOH}$ (rt, overnight, 2×500 mL). The solvent was removed under reduced pressure and the residue partitioned between hexanes (3×250 mL) and 9:1 MeOH/ H_2O (250 mL). The aqueous MeOH layer was concentrated and further partitioned

between *n*-BuOH (3 × 250 mL) and H₂O (250 mL). Removal of the solvent from the upper layer gave an *n*-BuOH extract (787 mg), a portion of which (191 mg) was adsorbed onto a solid phase extraction cartridge (C₁₈) and eluted with 4:1 CH₃CN/H₂O, followed by THF. The first-eluting fraction (116 mg) was separated by gradient HPLC (C₁₈, 10:90 to 60:40 CH₃CN/H₂O + 0.1% TFA) to give oroidin **1a** (8.8 mg, 1.0% wt weight).

MALDI FTMS of Oroidin (1a) and 7-¹⁵N-Oroidin (1d)

Matrix solution (1 μL of saturated α-cyano-4-hydroxycinnamic acid (CHCA) solution in 50:50:0.2 MeOH:H₂O:TFA) was added to 1 μL of the sample solution (1 pmol/μL) and the sample (approximately 1 pmol) deposited onto a stainless steel target. For each sample, 200 shots were acquired for each mass spectrum (acquisition time, ~1 minute each), and 24 spectra were co-added. Data were processed using Bruker software and error analysis was carried out using standard deviation of replicate MS measurements (*N* 5).

1D ¹H-¹⁵N HSQC Experiments

Samples for mixing experiments were prepared by addition of measured aliquots of a standard solution of **1d** (1.25 mg/10 mL MeOH) to a sample of **1a** (1500 μg). The samples were concentrated by removal of solvent (MeOH + 0.05% TFA), and redissolved in 1:1 DMSO-*d*₆/benzene-*d*₆ (35 μL) before transferring ~30 μL to a NMR tube (φ = 1.7 mm) using a gas-tight syringe. 1D ¹H-¹⁵N HSQC NMR spectra were acquired with 8K data points in T2 (no zero-fill) and optimized for ¹*J*_{N-H} = 90 Hz. Each experiment was preceded by 16 dummy scans and ~6K scans were collected. The corresponding ¹H-¹⁵N integrals were averaged and normalized against the N1 pyrrole couplet of **1** (*I*_p = 1.000). See Table 1 (numbering system follows that of Assman and Köckxxxii). ¹H-¹⁵N assignments: δ_H, δ_N (1:1 DMSO-*d*₆/C₆D₆): 13.14, 169.1 (N1); 8.75, 107.8 (N7); 13.54, 134.7 (N12); 12.78, 137.7 (N14); 8.21, 62.2 (N16).

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We thank A. Jansma (UCSD) for assistance with NMR, J. Pawlik (UNC Wilmington), and the captain and crew of the *RV Seward Johnson* for logistical support during collecting expeditions and in-field assays. We are grateful to the NIH (GM052964 DR & TFM) and the Welch Foundation (A-1280) for generous support.

References

- i. Recent examples of syntheses of pyrrole-imidazole alkaloids: Arndt H-D, Koert U. Schmalz H-G. *Organic Synthesis Highlights* 4. 2000:241. Wiley-VCH Weinheim; Hoffmann H, Lindel T. *Synthesis*. 2003:1753–1783.; Jacquot DEN, Lindel T. *Curr. Org. Chem.* 2005; 9:1551–1565.; Du H, He Y, Sivappa R, Lovely C. J. *Synlett*. 2006:965–992.; Kock M, Grube A, Seiple IB, Baran PS. *Angew. Chem.* 2007; 119:6706–6714.; *Angew. Chem. Int. Ed.* 2007; 46:6586–6594.; Weinreb SM. *Nat. Prod. Rep.* 2007; 24:931–948. [PubMed: 17898890] ; For some publications not covered in the these reviews, see: Dransfield PJ, Dilley AS, Wang S, Romo D. *Tetrahedron*. 2006; 62:5223–5247.; Wang S, Dilley AS, Poullennec KG, Romo D. *Tetrahedron*. 2006; 62:7155–7161.; Nakadai M, Harran PG. *Tetrahedron Lett.* 2006; 47:3933–3935.; Tan X, Chen C. *Angew. Chem., Int. Ed.* 2006; 45:4345–4348.; Overman LE, Paulini R, White NS. *J. Am. Chem. Soc.* 2007; 129:12896–2900. [PubMed: 17902668] ; O'Malley D, Yamaguchi J, Young IS, Seiple IB, Baran PS. *Angew. Chem. Int. Ed.* 2008; 47:3581–3583. ; Yamaguchi J, Seiple IB, Young IS, O'Malley DP, Maue M, Baran PS. *Angew. Chem. Int. Ed.* 2008; 47:3578–3580.; Bhandari MR, Sivappa R, Lovely CJ. *Org. Lett.* 2009; 11:1535–1538. [PubMed: 19278243]
- ii. Al Mourabit A, Potier P. *Eur. J. Org. Chem.* 2001:237–243.

- iii. Walker RP, Faulkner DJ, VanEngen D, Clardy J. J. Am. Chem. Soc. 1981; 103:6772–6773. An variation on the sceptrin skeleton, embodying an unusual benzocyclobutane (benzosceptrins A and B), has just been reported. Appenzeller J, Tilvi S, Martin M-T, Gallard J-F, El-bitar H, Dau ETH, Debitus C, Laurent D, Moriou C, Al-Mourabit A. Org. Lett. 2009; 11:4874–4877. [PubMed: 19863148]
- iv. Keifer, PA.; Koker, MES.; Schwartz, RE.; Hughes, RG., Jr.; Rittschof, D.; Rinehart, KL. 26th Interscience Conference on Antimicrobial Agents and Chemotherapy; New Orleans. Sep. 28–Oct. 1, 1986; No. 1281b Rinehart KL. Pure Appl. Chem. 1989; 6:525–528.c Kobayashi J, Tsuda M, Murayama T, Nakamura H, Ohizumi Y, Ishibashi M, Iwamura M, Ohta T, Nozoe S. Tetrahedron. 1990; 46:5579–5586.d Keifer PA, Schwartz RE, Koker MES, Hughes RG, Rittschof D, Rinehart KL. J. Org. Chem. 1991; 56:2965–2975.e Williams DH, Faulkner DJ. Tetrahedron. 1996; 52:5381–5390.
- v. Nishimura S, Matsunaga S, Shibasaki M, Suzuki K, Furihata K, van Soest RWM, Fusetani N. Org. Lett. 2003; 5:2255–2257. [PubMed: 12816422]
- vi. a Kinnel RB, Gehrken H-P, Scheuer PJ. J. Am. Chem. Soc. 1993; 115:3376–3377.b Kinnel RB, Gehrken H-P, Swali R, Skoropowski G, Scheuer PJ. J. Org. Chem. 1998; 63:3281–3286.
- vii. a Bascombe KC, Peter SR, Tinto WF, Bissada SM, McLean S, Reynolds WF. Heterocycles. 1998; 48:1461–1464.b Urban S, de A. Leone P, Carroll AR, Fechner GA, Smith J, Hooper JNA, Quinn RJ. J. Org. Chem. 1999; 64:731–735. [PubMed: 11674140]
- viii. Grube A, Kock M. Org. Lett. 2006; 8:4675–4678. [PubMed: 17020275]
- ix. D'Ambrosio M, Guerriero A, Debitus C, Ribes O, Pusset J, Leroy S, Pietra F. J. Chem. Soc. Chem. Commun. 1993:1305–1306.
- x. D'Ambrosio M, Guerriero A, Chiasera G, Pietra F. Helv. Chim. Acta. 1994; 77:1895–1902.
- xi. Hong TW, Jiménez DR, Molinski TF. J. Nat. Prod. 1998; 61:158–161. [PubMed: 9461668]
- xii. a De Nanteuil G, Ahond A, Guilhem J, Poupat C, Tran Huu Dau E, Potier P, Pusset M, Pusset J, Laboute P. Tetrahedron. 1985; 41:6019–6033.b Poullennec KG, Romo D. J. Am. Chem. Soc. 2003; 125:6344–6345. [PubMed: 12785755] c Imaoka T, Iwamoto O, Noguchi K, Nagasawa K. Angew. Chem. Int. Ed. 2009; 48:3799–3801.
- xiii. Mason CK, McFarlane S, Johnston PG, Crowe P, Erwin PJ, Domostoj MM, Campbell FC, Manaviazar S, Hale KJ, El-Tanani M. Mol. Cancer Ther. 2008; 7:548–558. [PubMed: 18347142]
- xiv. Foley LH, Büchi G. J. Am. Chem. Soc. 1982; 104:1776–1777.
- xv. Baran PS, O'Malley D, Zografos A. Angew. Chem. Int. Ed. 2004; 43:2674–2677.
- xvi. Baran was unable to convert **2** to **3** under photochemical conditions, however, thermal isomerization of **2** to **3** was achieved under microwave irradiation (195 °C, 1 min, 40% yield and 52% recovered starting material). See Reference xva.
- xvii. Hoffmann H, Lindel T. Synthesis. 2003:1753–1783. and references cited.
- xviii. a Birman VB, Jiang X-T. Org. Lett. 2004; 6:2369–2371. [PubMed: 15228281] b Papeo G, Frau MAG-Z, Borghi D, Varasi M. Tetrahedron Lett. 2005; 46:8635–8638.c Yang C-G, Wang J, Jiang B. Tetrahedron Lett. 2002; 43:1063–1066.
- xix. a Baran PS, Zografos AL, O'Malley DP. J. Am. Chem. Soc. 2004; 126:3726–3727. [PubMed: 15038721] b Huigens RW, Richards JJ, Parise G, Ballard TE, Zeng W, Deora R, Melander C. J. Am. Chem. Soc. 2007; 129:6966–6967. [PubMed: 17500516]
- xx. a Nanteuil GD, Ahond A, Poupat C, Thoison O, Potier P. Bull. Soc. Chim. Fr. 1986:813–816.b Commerçon A, Paris JM. Tetrahedron Lett. 1991; 32:4905–4906.c Danios-Zeghal S, Mourabit AA, Ahond A, Poupat C, Potier P. Tetrahedron. 1997; 53:7605–7614.d Lindel T, Hochgürter M. J. Org. Chem. 2000; 65:2806–2809. [PubMed: 10808460] e Berree F, Bleis PG, Carboni B. Tetrahedron Lett. 2002; 43:4935–4938.
- xxi. Lovely CJ, Du H, Sivappa R, Bhandari MR, He Y, Dias HVR. J. Org. Chem. 2007; 72:3741–3749. [PubMed: 17425369]
- xxii. a Pirrung MC, Pei T. J. Org. Chem. 2000; 65:2229–2230. [PubMed: 10774052] b Dolensky B, Kirk K. J. Org. Chem. 2002; 67:3468–3473. [PubMed: 12003561]
- xxiii. See Supporting Information for details.
- xxiv. Deuterium ^2H (~0.02%) and ^{17}O (~0.04%) also contribute to M+1, but are much lower in natural abundance (~0.02% and 0.04%, respectively) and may be ignored in the first approximation.

- xxv. The $^{13}\text{C}/^{15}\text{N}$ isotope ratio of *synthetic* and *natural* oroidin samples may differ slightly due to differences in fractionation of ^{13}C (or ^{15}N) in compounds derived by 'modern' biosynthesis compared to chemical precursors derived from petrochemical based feedstock. In practice, this will be inconsequential, since corrections can be made with the appropriate normalization.
- xxvi. The value here, given in commonly used units of $\gamma/2\pi$, was converted from the value cited in the IUPAC 2001 recommendations [$-2.71261804 = \gamma/10^7$ ($\text{rads}^{-1}\text{T}^{-1}$)]. Harris RK, Becker ED, Cabral de Menezes SM, Goodfellow R, Granger P. Pure Appl. Chem. 2001; 73:1795–1818.
- xxvii. Andrade P, Willoughby R, Pomponi S, Kerr R. Tetrahedron Lett. 1999; 40:4775–4778.
- xxviii. *Teichaxinella morchella* has synonymity with *Axinella corrugata* and is probably the same as *Stylissa caribica*. <http://www.spongeguide.org/speciesinfo.php?species=110>
- xxix. Stevensine was named in honor of the late Professor Robert V. Stevens (Department of Chemistry and Biochemistry, University of California, Los Angeles). Albizati K, Faulkner DJ. J. Org. Chem. 1985; 50:4163–4164.
- xxx. Englander J, Cohen L, Arshava B, Estephan R, Beckers JM, Naider F. Biopolymers. 2006; 84:508–518. [PubMed: 16741986]
- xxxi. Assman M, Köck MZ. Naturforsch. 2002; 57c:157–160.
- xxxii. Assman M, Zea S, Köck M. J. Nat. Prod. 2001; 64:1593–1595. [PubMed: 11754625]

Figure 1.

Oroidin (**1a**) and other representatives of the pyrrole-imidazole alkaloid (PIA) family from marine sponges.

Scheme 1. Retrosynthetic analysis of 7-¹⁵N-oroidin (**1d**) from urocanic acid.

Scheme 2. Synthesis of ¹⁵N-labeled oroidin.^a

^aReagents and conditions: (a) AcCl, MeOH, reflux, quant.; (b) TrCl, Et₃N, DMF; (c) DIBAL-H, THF; (d) TBSCl, imidazole, 74% for 3 steps; (e) *n*-BuLi, TsN₃, THF, 94%; (f) TBAF, THF, 82%; (g) MsCl, Et₃N, THF; (h) potassium phthalimide-¹⁵N, DMF, 42% for 2 steps; (i) NH₂NH₂, EtOH, 50 °C; (j) 4,5-dibromo-2-trichloroacetylpyrrole, Na₂CO₃, DMF, 76% for 2 steps; (k) AcCl, MeOH/EtOAc, 99%; (l) H₂/Pd-Lindlar, MeOH/THF, 84%.

Figure 2. MALDI FTMS (7T) expansions of the pseudomolecular ion $[M+H]^+$ of oroidin for (a) natural **1a** ($C_{11}H_{12}Br_2^{14}N_5NO$) and (b) 7- ^{15}N -oroidin (**1d**), $C_{11}H_{12}Br_2Br_2^{14}N_4^{15}NO$, >98% atom ^{15}N . Mass accuracy = 1 ppm.

Figure 3.

MALDI FTMS (7T) expansions of m/z and peak height, h , for the 'M+1' peak of the pseudomolecular ions of oroidin ($C_{11}H_{11}Br_2N_5O$). Mass accuracy = 1 ppm ($R = 240,000$). (a) natural **1a**. (b) **1a** + **1d** (0.04 mol equiv). (c) **1a** + **1d** (0.10 mol equiv). Peak assignments of $[M+H]^+$ in (c): m/z 388.94372, $^{12}C_{10}^{13}CH_{12}Br_2N_5O^+$; m/z 388.93739; $^{12}C_{11}H_{12}Br_2N_4^{15}NO^+$. The unrelated peak at m/z 388.9305 (indicated with an '*') is tentatively assigned to some loss of H from the dominant $^{79}Br/^{81}Br$ isotopomer, $C_{11}H_{10}^{79}Br^{81}BrN_5O^+$ ($[M]^+$, $\Delta m_{mu} = -0.5$).

Figure 4. 2D ^1H - ^{15}N HSQC (600 MHz, 1:1 DMSO- d_6 /benzene- d_6) of natural oroidin (**1a**, depicted tautomer is arbitrary). N locants are labeled following the numbering scheme of Assman and Köck (Ref.xxxii). ns = 16, T2, T1 = $2\text{K} \times 256$; F2, F1 = $2\text{K} \times 1\text{K}$; d1 = 1.5s

Figure 5. 1D ^1H - ^{15}N HSQC experiments (^1H δ , 1.7 mm microcryoprobe, 600 MHz) of **1a** with N-H assignments. Labels indicate N atom assignments made from a separate ^1H - ^{15}N HMBC experiment (not shown). (a) 1500 μg of **1a**, no added [^{15}N]-**1d**. (b) 1500 μg **1a** + 10 μg **1d**. (c) 1500 μg **1a** + 5.0 μg **1d**. (d) 1500 μg **1a** + 2.5 μg . Relaxation delay, $d_1 = 1.50$ s, optimized for $^1J_{\text{N-H}} = 90$ Hz; ^1H $\pi/2$ pulse = 12 μs , ^{15}N $\pi/2$ pulse = 34 μs ; NA = 6K; dummy scans = 16; NI = 1; T2 = F2 = 8K points (no zero fill). See Supporting Information for calculations of limit of detection (LOD), mean and SD.

Figure 6.

Linear regression of ^1H - ^{15}N HSQC cross-peak integral ratio, $(I - I_0)/I_0$ for the $\text{NH}(\text{C}=\text{O})$ signal in 'mock' pulse labeling experiments with natural abundance **1a** ($1500 \mu\text{g}$, I_0) spiked with measured aliquots of **1d** (μg , 'x-scale'). Observed values, I , for the $\text{NH}-\text{C}=\text{O}$ ^1H - ^{15}N couplet are normalized to the intensity of I_{py} the pyrrole N-H cross peak. For the $\text{NH}(\text{C}=\text{O})$ peak in the natural abundance sample (no added **1d**), $I = I_0$ and $I_0/I_{\text{py}} = 1.00$. Error bars are $\pm$ SD.

Figure 7.
Possible biosynthesis of oroidin (1a) and conversion to stevensine (17)

Table 1

Integrals from ^1H - ^{15}N 1D HSQC of natural oroidin (**1a**, 1.5 mg/ 30 μL) and **1a** 'spiked ' with **1d**. Integrals of H-N couplets corresponding to N-12, N-14 and N-16 vary due to tautomerism.

Aliquot μg 1d	N-12	N-1	N-14	N-7	N-16
0.0	1.26	1.00	1.05	2.17	2.14
2.5	1.03	1.00	0.48	2.57	2.23
5.0	1.65	1.00	1.18	3.83	2.55
10.0	0.63	1.00	0.00	5.74	3.02